Suppr超能文献

抗氧化酶作为心脏保护和心血管疾病治疗的潜在靶点。酶抗氧化剂:对抗氧化应激的药理学新进展。

Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress.

作者信息

Maksimenko Alexander V, Vavaev Alexander V

机构信息

Institute of Experimental Cardiology, Russian Cardiology Research-and-Production Complex, Moscow, Russia.

出版信息

Heart Int. 2012 Feb 3;7(1):e3. doi: 10.4081/hi.2012.e3.

Abstract

The focus in antioxidant research is on enzyme derivative investigations. Extracellular superoxide dismutase (EC-SOD) is of particular interest, as it demonstrates in vivo the protective action against development of atherosclerosis, hypertension, heart failure, diabetes mellitus. The reliable association of coronary artery disease with decreased level of heparin-released EC-SOD was established in clinical research. To create a base for and to develop antioxidant therapy, various SOD isozymes, catalase (CAT), methods of gene therapy, and combined applications of enzymes are used. Covalent bienzyme SOD-CHS-CAT conjugate (CHS, chondroitin sulphate) showed high efficacy and safety as the drug candidate. There is an evident trend to use the components of glycocalyx and extra-cellular matrix for target delivery of medical substances. Development of new enzyme antioxidants for therapeutic application is closely connected with progress in medical biotechnology, the pharmaceutical industry, and the bioeconomy.

摘要

抗氧化剂研究的重点在于酶衍生物的研究。细胞外超氧化物歧化酶(EC-SOD)尤其受到关注,因为它在体内显示出对动脉粥样硬化、高血压、心力衰竭、糖尿病发展的保护作用。临床研究证实了冠状动脉疾病与肝素释放的EC-SOD水平降低之间存在可靠关联。为了建立抗氧化治疗的基础并开发抗氧化疗法,人们使用了各种超氧化物歧化酶同工酶、过氧化氢酶(CAT)、基因治疗方法以及酶的联合应用。共价双酶SOD-CHS-CAT共轭物(CHS,硫酸软骨素)作为候选药物显示出高疗效和安全性。使用糖萼和细胞外基质成分进行药物靶向递送有明显趋势。用于治疗应用的新型酶抗氧化剂的开发与医学生物技术、制药行业和生物经济的进展密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f624/3366299/d9da5f2c2fcc/hi-2012-1-e3-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验